Heightened misuse risk and addictive potential of gabapentinoids: the fate of effective anxiolytics
Dusunen Adam: The Journal of Psychiatry and Neurological Sciences · 2019
DOI: 10.14744/dajpns.2019.00013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dusunen Adam: The Journal of Psychiatry and Neurological Sciences, 2019. Verfasst von Cuneyt Evren.
Abstract (Originalsprache)
Gabapentin and pregabalin, two pharmacologically very closely related substances, are classed as gabapentinoids (1).Gabapentin was synthesized in 1977 to create a structural analogue to gammaaminobutyric acid (GABA) with a higher degree of lipophilia than the original neurotransmitter.In 1993, its use in the treatment of epilepsy began.Pregabalin, another structural analogue of GABA, was synthesized in 1991; in 2004, it was introduced for the treatment of neuropathic pain and in 2005 for the therapy of refractory epilepsy.A third member of this drug family, mirogabalin, is currently undergoing clinical trials for the treatment of diabetic neuropathy, fibromyalgia, and postherpetic neuralgia (2).Gabapentinoids are commonly used in neurology, psychiatry, and primary healthcare.In Europe, pregabalin is used in the treatment of epilepsy (partial seizures), neuropathic pain, and generalized anxiety disorder.In the U.S.A., while it is not licensed for anxiety, it also has been licensed for fibromyalgia and postherpetic neuralgia.In addition, the molecule is often prescribed off-label for a number of clinical conditions, including post-traumatic stress disorder, somatoform disorders, bipolar disorder, alcohol or substance withdrawal processes, attention-deficit hyperactivity disorder (ADHD), insomnia, restless leg syndrome, borderline personality disorder, menopausal problems, chronic prostatitis, vertigo, itching disorder, migraine, trigeminal neuralgia, postoperative pain, and non-neuropathic pain disorders (3-5).It is estimated that off-label use of gabapentin makes up 83-95%
Zitieren
APA
Evren, C. (2019). Heightened misuse risk and addictive potential of gabapentinoids: the fate of effective anxiolytics. Dusunen Adam: The Journal of Psychiatry and Neurological Sciences. https://doi.org/10.14744/dajpns.2019.00013
Vancouver
Evren C. Heightened misuse risk and addictive potential of gabapentinoids: the fate of effective anxiolytics. Dusunen Adam: The Journal of Psychiatry and Neurological Sciences. 2019. doi:10.14744/dajpns.2019.00013
BibTeX
@article{Evren2019,
author = {Evren, Cuneyt},
title = {Heightened misuse risk and addictive potential of gabapentinoids: the fate of effective anxiolytics},
journal = {Dusunen Adam: The Journal of Psychiatry and Neurological Sciences},
year = {2019},
doi = {10.14744/dajpns.2019.00013}
}
EUVIMED